Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBZN7J)

• Drug Name: Litifilimab Drug Info
• Synonyms: BIIB059

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous lupus erythematosus	EB5Z	Phase 3	[1]
Systemic lupus erythematosus	4A40.0	Phase 3	[2]

• Cross-matching ID: TTD Drug ID: DMBZN7J

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-type lectin domain family 4 member C (CLEC4C)	TT7YT06	CLC4C_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT05531565) A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST). U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05352919) A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. U.S.National Institutes of Health.
• [3] Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. N Engl J Med. 2022 Jul 28;387(4):321-331.